Cite
HARVARD Citation
Aranow, C. et al. (n.d.). 178 Phase 2 trial of induction therapy with anti-CD20 (Rituximab) followed by maintenance therapy with anti-BAFF (Belimumab) in patients with active lupus nephritis. Lupus science & medicine. pp. A136-A137. [Online].